Atea registers Phase 1 first-in-human trial of AT-587 for hepatitis E
Atea Pharmaceuticals is recruiting healthy adult volunteers in Belgium for a single and multiple ascending dose study of oral candidate AT-587.
Atea Pharmaceuticals had one clinical trial update in the registry this week.
- A Phase 1, first-in-human, randomized, double-blind, placebo-controlled single and multiple ascending dose trial of AT-587 in healthy adult participants is recruiting, targeting hepatitis E.1 The study lists an estimated enrollment of 62 participants1, with a start date of July 13, 2026 and primary completion estimated for December 2026. The trial is assessing pharmacokinetics of AT-587 including Cmax and AUC1 and enrolling at a single site in Edegem, Belgium.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.